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ttp://dx.doi.org/10.1016/j.ajpath.2013.09.001Tumor necrosis factor (TNF-a) is a proinﬂammatory cytokine that plays a critical role in the pathogenesis of
inﬂammatory bowel disease. TNF-a causes an increase in intestinal permeability; however, the signaling
pathways and the molecular mechanisms involved remain unclear. The major purpose of this study was to
investigate the role ofMAP kinase pathways (ERK1/2 andp38 kinase) and themolecular processes involved. An
in vitro intestinal epithelial model system consisting of Caco-2 monolayers and an in vivomouse model system
were used to delineate the cellular and molecular mechanisms involved in TNF-a effects on tight junction
barrier. The TNF-aeinduced increase in Caco-2 tight junction permeability was mediated by activation of the
ERK1/2 signaling pathway, but not the p38 kinase pathway. Activation of the ERK1/2 pathway led to phos-
phorylation and activation of the ETS domain-containing transcription factor Elk-1. The activated Elk-1
translocated to the nucleus, where it bound to its binding motif on the myosin light chain kinase (MLCK)
promoter region, leading to theactivationofMLCKpromoter activity andgene transcription. Inaddition, in vivo
intestinal perfusion studies also indicated that the TNF-aeinduced increase in mouse intestinal permeability
requires ERK1/2-dependent activation of Elk-1. These studies provide novel insight into the cellular and mo-
lecular processes that regulate the TNF-aeinduced increase in intestinal epithelial tight junction permeability.
(Am J Pathol 2013, 183: 1871e1884; http://dx.doi.org/10.1016/j.ajpath.2013.09.001)Supported by a Veterans Affairs Merit Review grant from the Veterans
Affairs Research Service and by NIH grants R01-DK064165 and R01-
DK081429 (T.Y.M.).Defective intestinal epithelial tight junction (TJ) barrier
characterized by an increase in intestinal permeability is an
important pathogenic factor contributing to the development
of intestinal inﬂammation.1e3 In various inﬂammatory dis-
eases of the gut, including Crohn’s disease, ulcerative co-
litis, celiac disease, and a number of infectious diarrheal
syndromes, the disturbance in the intestinal TJ barrier al-
lows increased antigenic penetration, contributing to the
intestinal inﬂammatory response.3e5 Tumor necrosis factor
(TNF-a) is an essential mediator of inﬂammation in the
gut.6,7 TNF-a levels are markedly elevated in patients with
inﬂammatory conditions of the gut.8,9 It is well established
that TNF-a causes an increase in intestinal TJ permeability
in vivo and in vitro, which allows increased intestinal
permeation of luminal antigens.10e12 Animal studies have
shown that enhancement of the intestinal TJ barrier prevents
cytokine-mediated development of intestinal inﬂammation
and diarrhea.13,14 Clinical studies have shown that antie
TNF-a therapy leads to a retightening of the intestinal barrierstigative Pathology.
.and that the normalization of intestinal permeability is
associated with long-term clinical remission.7 In this regard,
understanding the intracellular pathways and molecular
mechanisms that mediate the TNF-aeinduced increase in
intestinal permeability is important for identifying potential
therapeutic targets and developing therapeutic strategies to
prevent disturbance of the intestinal TJ barrier and conse-
quent antigenic penetration.
Previous studies from our research group and others have
shown that TNF-a causes an increase intestinal epithelial TJ
permeability6,15e18 and indicated that myosin light chain
kinase (MLCK) plays a central role in the TNF-aeinduced
increase in intestinal permeability.6,17e19 TNF-a caused an
increase in intestinal expression of MLCK, and inhibition
of MLCK protein synthesis or MLCK activity prevented
Al-Sadi et althe TNF-aeinduced increase in intestinal permeability.
Furthermore, the increase in MLCK protein expression was
directly related to up-regulation of MLCK gene activity and
increase in mRNA transcription.6,19 The targeted inhibition
of MLCK and preservation of intestinal TJ barrier also
resulted in inhibition of intestinal inﬂammation in various
animal models of intestinal inﬂammation.20,21 However, the
intracellular signaling pathways and the precise molecular
mechanisms that mediate TNF-aeinduced activation of the
MLCK gene and subsequent increase in intestinal perme-
ability remain unclear. Mitogen-activated protein kinases
(MAPK), including extracellular regulated protein kinase 1/
2 (ERK1/2) and p38 kinase, have been suggested to play an
important role in mediating proinﬂammatory actions of
TNF-a, including cell growth, differentiation, stress, and
inﬂammatory responses.22e25 We hypothesized that TNF-a
modulation of intestinal epithelial TJ permeability is medi-
ated by MAPK pathway regulation of MLCK.
The major aims of the present studies were to investigate
the intracellular signaling pathways and the molecular mech-
anisms that regulate TNF-a modulation of intestinal TJ
permeability. We used both in vitro (ﬁlter-grown Caco-2
monolayers) and in vivo (live mouse intestinal perfusion)
model systems to assess the intracellular and molecular
mechanisms involved and to validate the in vivo relevance of
the signaling and molecular pathways. We tested the hypoth-
esis that the ERK1/2 or p38 kinase signaling pathway plays a
key regulatory role in TNF-aeinduced activation of MLCK
and the subsequent increase in intestinal epithelial perme-
ability. Our data suggest that the TNF-aeinduced increase in
intestinal TJ permeability is mediated by activation of the
ERK1/2 signaling pathway, but not the p38 kinase pathway.
Our data also suggest that ERK1/2 activation of nuclear tran-
scription factor Elk-1 regulatesMLCK gene activity by binding
to the serum response element on theMLCK promoter region.
Materials and Methods
Chemicals
Cell culture media (Dulbecco’s modiﬁed Eagle’s medium),
trypsin, fetal bovine serum, and related reagentswere purchased
from Life Technologies (Carlsbad, CA), as were glutamine,
penicillin, streptomycin, and PBS.AntieERK1/2 (extracellular
signal-regulated kinase 1/2), p-ERK1/2,Elk-1 (Ets-like gene 1),
and p-Elk-1 antibodies were purchased from Abcam (Cam-
bridge, MA). MLCK and antieb-actin antibodies were pur-
chased from Sigma-Aldrich (St. Louis, MO). Horseradish
peroxidaseeconjugated secondary antibodies for Western blot
analysis were purchased from Life Technologies and Abcam
(Cambridge, MA). siRNA of ERK1/2 and Elk-1 and trans-
fection reagents were purchased from Dharmacon (Thermo
Scientiﬁc, Pittsburgh, PA). The ERK1/2 inhibitor PD 98059
was purchased from Sigma-Aldrich. All other chemicals were
purchased from Sigma-Aldrich, VWR International (West
Chester, PA), Life Technologies, or Fisher Scientiﬁc.1872Cell Cultures
Caco-2 cells (passage 18 to 26) purchased from the ATCC
(Manassas, VA) were maintained at 37C in a 5% CO2-
enriched atmosphere, and they were kept in a culture me-
dium composed of Dulbecco’s modiﬁed Eagle’s medium
with 4.5 mg/mL glucose, 50 U/mL penicillin, 50 U/mL
streptomycin, 4 mmol/L glutamine, 25 mmol/L HEPES, and
10% fetal bovine serum.
Determination of Epithelial Monolayer Resistance and
Paracellular Permeability
An epithelial voltohmmeter (World Precision Instruments,
Sarasota, FL) was used for measurement of the transepi-
thelial electrical resistance (TER) of ﬁlter-grown Caco-2
intestinal monolayers, as previously reported.26,27 The effect
of TNF-a on Caco-2 paracellular permeability was deter-
mined using an established paracellular marker, inulin, with
a molar mass of 5000 g/mol.26,28 For transepithelial and
permeability studies, Caco-2eplated ﬁlters having TER of
400 to 500 U,cm2 were used. A known concentration (2
mmol/L) of radiolabeled inulin (14C) was added to the apical
solution.
Assessment of Protein Expression by Western Blot
Analysis
Caco-2 monolayers were treated with 10 ng/mL TNF-a for
varying time periods. At the end of the experimental period,
Caco-2 monolayers were immediately rinsed with ice-cold
PBS, and cells were lysed with lysis buffer [50 mmol/L
Tris,HCl (pH 7.5), 150 mmol/L NaCl, 500 mmol/L NaF,
2 mmol/L EDTA, 100 mmol/L vanadate, 100 mmol/L phe-
nylmethylsulfonyl ﬂuoride, 1 mg/mL leupeptin, 1 mg/mL
pepstatin A, 40 mmol/L paranitrophenyl phosphate, 1 mg/
mL aprotinin, and 1% Triton X-100) and scraped, and the
cell lysates were placed in microcentrifuge tubes. Cell ly-
sates were centrifuged to yield a clear lysate. Supernatant
was collected, and protein measurement was performed
using a Bio-Rad protein assay kit (Bio-Rad Laboratories,
Hercules, CA). Laemmli gel loading buffer was added to the
lysate containing 20 mg of protein and boiled for 7 minutes,
after which proteins were separated on SDS-PAGE gel.
Proteins from the gel were transferred to a nitrocellulose
membrane (Bio-Rad Laboratories) overnight. The membrane
was incubated for 2 hours in blocking solution (5% nonfat
dried milk in Tris-buffered salineeTween 20 buffer). The
membrane was incubated with appropriate primary antibodies
in blocking solution. Primary antibodies were used in con-
centrations according to the manufacturer’s recommendations
(usually 1 to 2 mg/mL). After being washed in Tris-buffered
salinee1% Tween buffer, the membrane was incubated in
appropriate secondary antibodies (1:2000). After a washing in
Tris-buffered salinee1%Tween 20 buffer, themembrane was
developed using Luminol Western blotting reagents (Santaajp.amjpathol.org - The American Journal of Pathology
TNF-a, TJ Barrier, and ERK1/2 SignalingCruz Biotechnology, Santa Cruz, CA) on Kodak BioMaxMS
ﬁlm (Fisher Scientiﬁc).RNA Isolation and Reverse Transcription
Caco-2 cells (5  105/ﬁlter) were seeded into six-well
Transwell permeable inserts (Corning Life Sciences, Tewks-
bury, MA) and grown to conﬂuency. Filter-grown Caco-2
cells were then treated with the appropriate experimental re-
agents for the desired time periods. At the end of the experi-
mental period, cells were washed twice with ice-cold PBS.
Total RNA was isolated using an RNeasy kit (Qiagen,
Valencia, CA) according to themanufacturer’s protocol. Total
RNA concentrationwas determined by absorbance at 260/280
nm using a SpectraMax 190 microplate reader (Molecular
Devices, Sunnyvale, CA). The reverse transcription was per-
formed using an Applied Biosystems GeneAmp Gold RNA
PCR core kit (Life Technologies). From each sample, 2 mg of
total RNA was reverse-transcribed into cDNA in a 40-mL re-
action containing 1RT-PCRbuffer, 2.5mmol/LMgCl2, 250
mmol/L of each dNTP, 20 U RNase inhibitor, 10 mmol/L
dithiothreitol, 1.25 mmol/L random hexamer, and 30 U Mul-
tiScribe Reverse Transcriptase. The reverse-transcriptase re-
actions were performed in a thermocycler (PTC-100; MJ
Research, Waltham, MA) at 25C for 10 minutes, 42C for
30 minutes, and 95C for 5 minutes.qPCR Quantiﬁcation of Gene Expression
Quantitative real-time PCR (qPCR) was performed using an
ABI Prism 7900 sequence detection system and a TaqMan
universal PCR master mix kit (Life Technologies), as
described previously. Each qPCR reaction contained 10 mL
of reverse-transcriptase reaction mix, 25 mL of 2 TaqMan
universal PCR master mix, 0.2 mmol/L probe, and 0.6 mmol/L
primers. Primer and probe design for the qPCR was per-
formed using Applied Biosystems Primer Express software
version 2 (Life Technologies). The following primers were
used: MLCK-speciﬁc primers, forward 50-AGGAA-
GGCAGCATTGAGGTTT-30 and reverse 50-GCTTTCAG-
CAGGCAGAGGTAA-30; MLCK-speciﬁc probe, FAM 50-
TGAAGATGCTGGCTCC-30 TAMRA; internal control
GAPDH-speciﬁc primers, forward 50-CCACCCATGGCA-
AATTCC-30 and reverse 50-TGGGATTTCCATTGATGA-
CCAG-30; and GAPDH-speciﬁc probe, JOE 50-TGGCA-
CCGTCAAGGCTGAGAACG-30 TAMRA. All runs were
performed according to the default PCR protocol (50C for
2 minutes and 95C for 10 minutes, followed by 40 cycles
of 95C for 15 seconds, and then 60C for 1 minute). For
each sample, qPCR reactions were performed in triplicate,
and the average CT was calculated. A standard curve was
generated to convert the CT to copy numbers. Expression
of MLCK mRNA was normalized with GAPDH mRNA
expression. The average copy number of MLCK mRNA ex-
pression in control samples was set to 1.0. The relativeThe American Journal of Pathology - ajp.amjpathol.orgexpression of MLCK mRNA in treated samples was deter-
mined as a fold increase, relative to control samples.
siRNA of ERK1/2 and Elk-1
Targeted siRNAs were purchased from Dharmacon (Thermo
Scientiﬁc). Caco-2 monolayers were transiently transfected
using DharmaFECT transfection reagent (Thermo Scientiﬁc).
In brief, 5  105 cells/ﬁlter were seeded into a 12-well
Transwell plate and grown to conﬂuency. The Caco-2
monolayers were washed with PBS twice, and then 0.5 mL
of Accell delivery medium (Thermo Scientiﬁc) was added to
the apical compartment of each ﬁlter and 1.5 mLwas added to
the basolateral compartment of each ﬁlter. The siRNA of in-
terest (5 ng) and DharmaFECT reagent (2 mL) were added to
the apical compartment of each ﬁlter. The TNF-a experiments
were performed at 96 hours after transfection. The efﬁciency
of silencing was conﬁrmed by Western blot analysis.
ELISA-Based Determination of in Vitro ERK1/2 Kinase
Activity
For ELISA, biotinylated myelin basic protein (MBP) was
diluted in PBS and incubated on streptavidin-coated 96-well
plates at 37C for 1 hour. The plates were washed three times
with PBS, incubated with blocking solution (1 mg/mL bovine
serum albumin in PBS) at 37C for 1 hour, and then washed
three more times with PBS. Ninety microliters of kinase reac-
tion buffer [20 mmol/L Tris/HCl (pH 7.5), 10 mmol/LMgCl2,
50 mmol/L NaCl, 1 mmol/L dithiothreitol, 1 mmol/L NaF,
50 mmol/L ATP] provided by the manufacturer (MBL Inter-
national, Woburn, MA) and 10 mL of samples containing
immunoprecipitated ERK1/2 were added to each well, and the
kinase reaction (phosphorylation of MBP) was performed at
37C for 30 to 60 minutes. The reaction was stopped by
removing the reaction mixtures and washing the plates three
times with washing buffer [20 mmol/L Tris-HCl (pH 7.4), 0.5
mol/L NaCl, and 0.05% Tween 20]. The washed plates were
incubated with 5 ng/mL antiep-MBP antibody at room tem-
perature for 1 hour. The plates were washed four times with
washing buffer, and goat anti-rabbit IgG antibody (diluted
1:2000 inwashing buffer)was added to thewells, and the plates
were incubated at 37C for 1 hour. The plateswerewashed four
more times and incubated with 100 mL of substrate solution
tetramethylbenzidine at 37C for 5 to 15 minutes. To stop the
reaction, 100 mL of stop solution containing 0.5 N H2SO4 was
added. The absorbance at 450 nm was determined using a
SpectraMax 190 microplate reader (Molecular Devices).
Nuclear Extracts and ELISA for Transcription Factor
Activation
Filter-grown Caco-2 monolayers were treated with 10 ng/
mL TNF-a for 30 minutes. The Caco-2 monolayers were
washed with ice-cold PBS, scraped, collected, and centri-
fuged at 20,817  g for 30 seconds. The cell pellets were1873
Al-Sadi et alresuspended in 200mLof bufferA [10mmol/LHEPES-KOH,
1.5 mmol/L MgCl2, 10 mmol/L KCl, 0.5 mmol/L dithio-
threitol, and 0.2 phenylmethylsulfonyl ﬂuoride (pH 7.9)]
and incubated on ice for 15 minutes. After centrifugation at
14,000 rpm for 30 seconds, pelleted nuclei were resuspended
in 30 mL of buffer C [20 mmol/L HEPES-KOH (25% glyc-
erol), 420 mmol/L NaCl, 1.5 mmol/L MgCl2, 0.2 mmol/L
EDTA, 0.5 mmol/L dithiothreitol, and 0.2 mmol/L phenyl-
methylsulfonyl ﬂuoride (pH 7.9)]. After incubation on ice for
20 minutes, the lysates were centrifuged at 14,000 rpm for
20minutes. Protein concentrations were determined using the
Bradford method. The Elk-1 DNA-binding assay was per-
formed using TransAM ELISA-based kits from Active Motif
(Carlsbad, CA) according to the manufacturer’s protocol. In
brief, the binding reactions contained 1 pmol/L biotinylated
probe (Integrated DNA Technologies, Coralville, IA) and
5 mg of nuclear extract in complete binding buffer with a total
volume of 50 mL. After 30 minutes of incubation, the solution
was transferred to an individual well on 96-well plate and
incubated for 1 hour. The appropriate antibody (2mg/mL)was
added to the well to bind the target protein in nuclear extract.
After incubation for 1 hour, the antibody was removed, and
100 mL of horseradish peroxidaseeconjugated secondary
antibody was added to the well and incubated for 1 hour.
Subsequently, 100 mL of developing solution was added for 2
to 10 minutes, and then 100 mL of stop solution was added.
The absorbance at 450 nm was determined using a Spec-
traMax 190 microplate reader (Molecular Devices).
Cloning of the Full-Length MLCK Promoter Region and
Deletion Constructs
The MLCK promoter region was cloned using a Genome-
Walker system (ClontechLaboratories,MountainView, CA).
A 2091-bp DNA fragment (2109 to18) was ampliﬁed by
PCR. The ampliﬁcation condition was 94C for 2 minutes,
followed by 43 cycles at 94C for 1minute, 50C for 1minute,
and 72C for 2 minutes, and then 72C for 5 minutes. The
resultant PCR product was digested with HindIII and KpnI
and inserted into pGL3-basic luciferase reporter vector
(Promega, Madison, WI). The sequence was conﬁrmed at the
University of New Mexico DNA Research Services. Con-
struction of MLCK promoter reporter plasmids was per-
formed using the pGL3-basic luciferase reporter vector.
Deletions of MLCK promoter were performed according to
the PCR method. The PCR conditions were 94C for 2 mi-
nutes, followed by 43 cycles at 94C for 1 minute, 50C for
1minute, and 72C for 2minutes, and then 72C for 5minutes.
The resultant PCR products were cloned into pGL3-basic
luciferase reporter vector and the sequences were conﬁrmed.
Transfection of DNA Constructs and Assessment of
Promoter Activity
DNA constructs of MLCK promoters were transiently
transfected into Caco-2 cells using Lipofectamine 20001874transfection reagent (Life Technologies). Renilla lucif-
erase vector (pRL-TK; Promega) was cotransfected with
each plasmid construct, as an internal control. Cells (5 
105 per ﬁlter) were seeded into a six-well Transwell plate
and grown to conﬂuency. The Caco-2 monolayers were
washed with PBS twice, and then 1.0 mL of Opti-MEM
medium was added to the apical compartment of each
ﬁlter and 1.5 mL was added to the basolateral compart-
ment of each ﬁlter. One microgram of each plasmid
construct and 0.25 mg of pRL-TK or 2 mL of Lipofect-
amine 2000 (Life Technologies) were preincubated in 250
mL of Opti-MEM medium. After 5 minutes of incubation,
the two solutions were mixed and incubated for another
20 minutes, and the mixture was added to the apical
compartment of each ﬁlter. After incubation for 3 hours at
37C, 500 mL of Dulbecco’s modiﬁed Eagle’s medium
containing 10% fetal bovine serum were added to both
sides of the ﬁlter to reach a 2.5% ﬁnal concentration of
fetal bovine serum. Subsequently, the medium was
replaced with normal Caco-2 growth medium at 16 hours
after transfection.
Speciﬁc experiments were performed at 48 hours after
transfection. At the completion of speciﬁc experimental
treatments, Caco-2 cells were washed twice with 1 mL of
ice-cold PBS, and 400 mL of 1 passive lysis buffer was
added; cells were then incubated at room temperature for 15
minutes, scraped, transferred into an Eppendorf tube, and
centrifuged for 15 seconds at 13,000 rpm in a micro-
centrifuge. Luciferase activity was determined using a dual
luciferase assay kit (Promega). Twenty microliters of the
supernatant was used for each assay. Luciferase values were
determined using a Lumat LB 9507 luminometer (Berthold
Technologies, Oak Ridge, TN; Bad Wildbad, Germany).
The value of reporter luciferase activities were then divided
by that of Renilla luciferase activities to normalize for dif-
ferences in transfection efﬁciencies. The average activity
value of the control samples was set to 1.0. The luciferase
activity of MLCK promoter in treated samples was deter-
mined relative to control samples.
Site-Directed Mutagenesis
Mutagenesis of MLCK promoter was performed using an
Invitrogen GeneTailor site-directed mutagenesis system
(Life Technologies). In brief, primers were generated that
included the mutation site ﬂanked by a wild-type sequence
on either side (mutant primer, forward 50-CTGCAGGAAG-
GCAGCTCCCACAATTCCTTCTTTCTACCCCTGCCA-30
and reverse 50-TGGGAGCTGCCTTCCTGCAGGTGAAA-
GGCA-30). A PCR reaction produced a new complete copy of
the plasmid containing the mutation coded for by the primers.
The linear PCR product was subsequently transformed into
DH5-T1Escherichia coli, which circularized the PCR product
and digested any remaining parent plasmid. DNA sequence
was then veriﬁed at the University of New Mexico DNA
Research Services.ajp.amjpathol.org - The American Journal of Pathology
P-ERK1/2
ERK1/2
Time (min)              0          5         10        20       30      60 
0 5 10 20 30 60
0
4
8
12
Time (min)
R
e
la
tiv
e
 
ER
K1
/2
 
Ac
tiv
ity
*
*
*
*
*
Figure 1 Effect of TNF-a on ﬁlter-grown Caco-2 ERK1/2 activation. A:
TNF-a (10 ng/mL) causes a time-dependent increase in Caco-2 ERK1/2
phosphorylation; total ERK1/2 was used for equal protein loading. B: TNF-a
causes a time-dependent increase in ERK1/2 activity as determined by
ELISA-based in vitro kinase activity using MBP as the substrate. Data are
expressed as means  SEM. n Z 4. *P < 0.001 versus control.
TNF-a, TJ Barrier, and ERK1/2 SignalingIn Vivo Mouse Intestinal Permeability Measurements
The Laboratory Animal Care and Use Committee at the
University of New Mexico approved all experimental
protocols.
Mouse intestinal permeability was measured by recycling
small intestinal perfusion, as described previously.29e31
After the experimental period, mice were anesthetized
with isoﬂurane. After midline incision of the abdomen, 5 cm
of intestine segment was isolated and cannulated at the
proximal and distal ends with polyethylene tubing (0.76 mm
internal diameter). Flushing solution [140 mmol/L NaCl, 10
mmol/L HEPES (pH 7.4)] warmed to 37C was ﬁrst
perfused through the intestine at 1 mL/minute for 20 mi-
nutes, followed by air ﬂush to remove residual contents
using an external pump (Bio-Rad Laboratories). This was
followed by perfusion of 5 mL of perfusate solution [85
mmol/L NaCl, 10 mmol/L HEPES, 20 mmol/L sodium
ferrocyanide, 5 mmol/L KCl, 5 mmol/L CaCl2 (pH 7.4)]
containing Texas Redelabeled dextran 10K (10 kDa) in a
recirculating manner at 0.75 mL/minute for 2 hours. The
abdominal cavity was covered with moistened gauze, and
body temperature was measured via rectal thermometer;
body temperature was maintained at 37.5  0.5C using a
heating lamp. Aliquots (1 mL) of test solution were removed
at the beginning and end of the perfusion. After perfusion,
the animal was sacriﬁced, the perfused intestine segment
was excised, and the length was measured. The excised
intestinal loop was then snap-frozen in optimal cutting
temperature compound or was used for protein and RNA
analysis. Ferrocyanide concentration in the perfusate was
measured using a colorimetric assay. Texas Redelabeled
dextran 10K concentration was measured using an excita-
tion wavelength of 595 nm and an emission wavelength of
615 nm in a microplate reader.
Probe clearance was calculated as CprobeZ (CiVi CfVf)/
CavgTL, where C is the probe concentration and V is the
perfusate volume; the subscripts i, f, and avg indicate initial
measured, ﬁnal, and average values; T is perfusion time in
hours; and L is the length of the perfused intestine section in
centimeters. Vf was calculated as Vi([ferrocyanide]i/[ferro-
cyanide]f). Cavg was calculated as (Ci  Cf)/ln(Ci/Cf).
Animal Surgery and in Vivo Transfection of ERK1/2 and
Elk-1 siRNA
Mice were fasted for 24 hours before the surgery. Mice were
anesthetized with isoﬂurane (4% for surgical induction and
1% for maintenance) using oxygen as carrier during surgical
procedures. Surgical procedures were performed using
sterile technique. The abdomen was opened by a midline
incision, and a 6-cm segment of intestine was isolated at the
proximal and distal ends and tied with sutures. Next, 0.5 mL
of siRNA transfection solution (containing Accell medium,
2.5 nmol ERK1/2 or Elk-1 siRNA, and 50 mL of Lipofec-
tamine 2000 transfection reagent) was introduced into theThe American Journal of Pathology - ajp.amjpathol.orglumen of the isolated intestinal segment using a 30-G
needle for a 1-hour transfection period. Control animals
underwent sham surgery, for which the siRNA transfection
solution contained Accell medium, 2.5 nmol nontarget
siRNA, and 50 mL of Lipofectamine 2000 transfection
reagent. The abdominal cavity was covered with moist-
ened gauze. Body temperature was monitored continu-
ously with a rectal probe and was maintained at 37.5 
0.5C using a heating pad. After the 1-hour transfection
period, each end of the intestinal segment was untied, the
intestine was placed back into the abdominal cavity, and
the abdomen was closed. At 3 days after transfection,
functional studies of intestinal epithelial barrier were per-
formed. The surgery and the in vivo transfection pro-
cedures had no effect on food intake or body weight of the
animals during the experimental period. Animal weight
averaged between 23 and 25 g during the experimental
period.
Statistical Analysis
Statistical signiﬁcance of differences between mean values
was assessed with Student’s t-tests for unpaired data and
analysis of variance analysis whenever required. All re-
ported signiﬁcance levels represent two-tailed P values. A
P value of <0.05 was used to indicate statistical signiﬁ-
cance. Each experiment was performed in triplicate or
quadruplicate (n Z 3 or 4), and all experiments were re-
peated at least three times to ensure reproducibility.1875
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Figure 2 Effect of ERK1/2 inhibition by the pharmacological inhibitor PD 98059 (100 mmol/L) on Caco-2 ERK1/2 activity, TER, and paracellular
permeability. A and B: TNF-a (10 ng/mL) causes a time-dependent decrease in Caco-2 TER (A) and a time-dependent increase in mucosal-to-serosal ﬂux of the
paracellular marker inulin (B). C: Pretreatment with 100 mmol/L PD 98059 for 1 hour before TNF-a treatment inhibits the TNF-aeinduced increase in ERK1/2
in vitro kinase activity. D: PD 98059 prevents the TNF-aeinduced decrease in Caco-2 TER. E: Pretreatment with PD 98059 prevents the TNF-aeinduced increase
in mucosal-to-serosal inulin ﬂux. Data are expressed as means  SEM. nZ 4 (C); nZ 6 (A, B, D, and E). *P < 0.001 versus control. yP < 0.001 versus TNF-a
treatment.
Al-Sadi et alResults
The TNF-aeInduced Increase in Caco-2 TJ Permeability
Is Regulated by MAP Kinase Activation
We examined the possibility that the TNF-aeinduced in-
crease in Caco-2 TJ permeability is mediated by MAP kinase
activation. Because TNF-a has been shown to activate MAP
kinases ERK1/2 and p38 kinase in various cell types,24,25
these two kinase pathways were targeted. The time-course
effect of 10 ng/mL TNF-a on ERK1/2 or p38 kinase acti-
vation was determined by measuring ERK1/2 phosphoryla-
tion in ﬁlter-grown Caco-2 monolayers. TNF-a caused a
rapid increase in ERK1/2 phosphorylation in Caco-2 cells,
starting at about 10 minutes and continuing up to 60 minutes,
as determined by p-ERK1/2 immunoblotting (Figure 1A). In
contrast, TNF-a did not have a signiﬁcant effect on p38 ki-
nase phosphorylation (Supplemental Figure S1). The total
ERK1/2 level was not affected by the TNF-a treatment
(Figure 1A). The effect of TNF-a on ERK1/2 kinase activity
was also conﬁrmed by an ELISA-based in vitro kinase assay.
The kinase activity of immunoprecipitated ERK1/2 was
directly measured in vitro usingMBP as the substrate. TNF-a
caused a rapid increase in Caco-2 ERK1/2 kinase activity,1876starting at about 5 to 10 minutes (Figure 1B). These data
suggested that TNF-a causes a rapid activation (within mi-
nutes) of ERK1/2 (but not p38 kinase) in Caco-2 monolayers.
To determine the requirement of ERK1/2 activation in the
TNF-aeinduced increase in Caco-2 TJ permeability, the
effect of ERK1/2 inhibition was examined. Caco-2 TJ
permeability was determined by measuring Caco-2 TER or
transepithelial ﬂux of the paracellular marker inulin.26,28
TNF-a caused a time-dependent decrease in Caco-2 TER
and an increase in transepithelial ﬂux of inulin (Figure 2, A
and B). At 100 mmol/L, the ERK1/2 inhibitor PD 98059
inhibited TNF-aeinduced activation of ERK1/2, as as-
sessed by in vitro kinase activity (Figure 2C), and prevented
the decrease in TER (Figure 2D) and increase in inulin ﬂux
(Figure 2E). In contrast, the p38 kinase inhibitor SB 203580
did not have any effect on the TNF-aeinduced increase in
Caco-2 TJ permeability (Supplemental Figure S2). These
results suggested that ERK1/2 activation is required for the
TNF-aeinduced increase in Caco-2 TJ permeability.
To further conﬁrm the requirement of ERK1/2 for the
effect of TNF-a on Caco-2 TJ permeability, ERK1/2
expression was selectively knocked down by siRNA trans-
fection. Transfection of ERK1/2 siRNA caused a near-
complete depletion of ERK1/2 in ﬁlter-grown Caco-2ajp.amjpathol.org - The American Journal of Pathology
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Figure 3 Effect of siRNA-induced ERK1/2 knockdown on the TNF-
aeinduced increase in Caco-2 TJ permeability. A: ERK1/2 siRNA trans-
fection results in a near-complete depletion in ERK1/2 protein expression.
B and C: ERK1/2 siRNA transfection prevents the TNF-aeinduced decrease
in Caco-2 TER (B) and the TNF-aeinduced increase in inulin ﬂux (C). Data
are expressed as means  SEM. n Z 6. *P < 0.001 versus control. yP <
0.001 versus TNF-a treatment.
TNF-a, TJ Barrier, and ERK1/2 Signalingmonolayers (Figure 3A). The siRNA-induced knockdown
of ERK1/2 prevented the TNF-aeinduced decrease in
Caco-2 TER (Figure 3B) and increase in inulin ﬂux
(Figure 3C), conﬁrming the requirement of ERK1/2 in the
TNF-aeinduced increase in Caco-2 TJ permeability.
ERK1/2 Signaling Pathway Is Involved in the
Regulation of MLCK Gene and Protein Expression
Previous studies from our research group and others have
shown that the TNF-aeinduced increase in Caco-2 TJ per-
meability is mediated by an increase in MLCK protein
expression and activity.6,17e19 However, the intracellular
signaling pathways or the molecular mechanisms involved in
the TNF-a regulation of MLCK gene and protein expression
remain unclear. In the present study, we examined the
involvement of the ERK1/2 signaling pathway in TNF-a up-
regulation of MLCK gene and protein expression. TNF-a
caused an increase in Caco-2 MLCK mRNA and protein
expression (Figure 4, A and B). The inhibition of ERK1/2
with the pharmacological inhibitor PD 98059 (100 mmol/L)
prevented the TNF-aeinduced increase in MLCK mRNA
and protein expression (Figure 4, C and D). Similarly,
siRNA-induced knockdown of Caco-2 ERK1/2 also inhibi-
ted the TNF-aeinduced increase in MLCK mRNA and
protein level (Figure 4, E and F). Taken together, these data
suggested that the ERK1/2 signaling pathway mediates the
TNF-amodulation of MLCKmRNA and protein expression.
Transcription Factor Elk-1 Regulates MLCK Gene
Activity and TJ Permeability
Next, we examined the nuclear transcription factor and the
molecular determinants that regulate the TNF-aeinduced
increase inMLCK gene activity and Caco-2 TJ permeability.
Nuclear transcription factor Elk-1, a direct substrate of
ERK1/2, binds to serum response element on a promoter
region and regulates gene transcription.32e34 Using Pro-
moterInspector software (Genomatix, Munich, Germany),
we identiﬁed two Elk-1 binding motifs or serum response
elements on the MLCK promoter region. The effect of TNF-
a on Elk-1 activation was examined by measuring Elk-1
phosphorylation and by ELISA-based DNA binding assay.
TNF-a caused a time-dependent increase in Caco-2 Elk-1
phosphorylation (Ser383) (Figure 5A). TNF-a also caused
an increase in binding of activated Elk-1 (in the nuclear
fraction) to the Elk-1 binding sequence on the DNA probe
(Figure 5B). The ERK1/2 inhibitor PD 98059 inhibited the
TNF-aeinduced increase in Elk-1 phosphorylation and the
DNA binding of Elk-1 (Figure 5, C and D).
We then examined the regulatory role of Elk-1 on MLCK
promoter activity, using siRNA silencing of Elk-1 in Caco-2
monolayers. The transfection of ﬁlter-grown Caco-2 mono-
layers with Elk-1 siRNA caused a near-complete depletion
of Elk-1 expression (Figure 6A). TNF-a caused an increase
in MLCK promoter activity, and siRNA knockdown ofThe American Journal of Pathology - ajp.amjpathol.orgElk-1 prevented the increase in MLCK promoter activity
(Figure 6B). siRNA knockdown of Elk-1 also inhibited the
TNF-aeinduced increase inMLCK at themRNA and protein
levels (Figure 6, C and D) and the increase in Caco-2 TJ
permeability (Figure 6, E and F). Taken together, these data
suggested that Elk-1 activation is required for the increase in
MLCK gene activity and the subsequent increase in Caco-2 TJ
permeability.
Elk-1 Regulation of MLCK Promoter
Next, we determined the molecular determinants that mediate
the TNF-a modulation of MLCK promoter activity. As noted
above, two serum response elements or Elk-1 binding se-
quences were identiﬁed on theMLCK promoter region: site A,
between 1118 and 1102 (50-TGGCCTTCCTCCCTC-30),1877
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Figure 4 Effect of ERK1/2 inhibition on the
TNF-aeinduced increase in Caco-2 MLCK gene and
protein expression. A: TNF-a causes a time-
dependent increase in MLCK mRNA levels. The
average copy number of MLCK mRNA in controls was
4.63  1011. B: TNF-a causes a time-dependent in-
crease in MLCK protein expression. C: Pretreatment
with the ERK1/2 inhibitor PD 98059 1 hour before
TNF-a treatment prevents the TNF-aeinduced in-
crease in MLCK mRNA levels. D: The ERK1/2 inhibitor
PD 98059 prevents the TNF-aeinduced up-regulation
of MLCK protein expression. E: siRNA-induced
knockdown of ERK1/2 prevents the TNF-aeinduced
increase in MLCKmRNA. F: ERK1/2 siRNA transfection
prevents the TNF-aeinduced increase in MLCK pro-
tein expression. Data are expressed as means SEM.
nZ 8. Experimental period, 6 hours (C and E). *P<
0.001 versus control. yP < 0.001 versus TNF-a
treatment.
Al-Sadi et aland site B, between 310 and 296 (50-GAAAATGGAA-
GTCCAAG-30) (Figure 7A). Three MLCK promoter deletion
constructs were generated that contained both Elk-1 binding
motifs a and b (full-length promoter region) and DNA con-
structs that contained only the downstream binding site B.P-Elk-1
Elk-1
Time (min)          0       5       10      20       30    60 
0 5
0
2
4
6
8
10
*R
e
la
tiv
e
 
El
k-
1 
D
NA
 
Bi
n
di
n
g
Control TN
0
2
4
6
8
R
e
la
tiv
e
 
El
k-
1 
D
NA
 
Bi
n
di
n
g
C TNF          PD     TNF+PD
P-Elk-1
β actin
1878Two deletion constructs encoding the site B were generated:
MLCK926, which encodes the promoter region upstream of
the binding sequence B (310 to 296) and MLCK 313,
which encodes the sequence B but does not encode the up-
stream promoter region beyond 313.10 20 30 60
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Figure 5 Effect of TNF-a on Elk-1 activation. A:
TNF-a treatment results in a time-dependent in-
crease in Elk-1 phosphorylation. B: TNF-a causes a
time-dependent increase in Elk-1 activity as deter-
mined by ELISA-based binding assay. C: Pretreat-
ment with the ERK1/2 inhibitor PD 98059 for 1 hour
before TNF-a treatment prevents TNF-aeinduced
Elk-1 phosphorylation. D: Pretreatment with PD
98059 for 1 hour before TNF-a treatment prevents
TNF-aeinduced binding of Elk-1 to its binding site
on DNA probe as determined by DNA ELISA binding
assay. Data are expressed as means  SEM. nZ 4.
*P< 0.001 versus control. yP< 0.001 versus TNF-a
treatment.
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Figure 6 A: Elk-1 siRNA transfection results in a near-complete depletion in Elk-1 protein expression in ﬁlter-grown Caco-2 monolayers. B: Elk-1 siRNA
transfection signiﬁcantly prevents the TNF-aeinduced increase in Caco-2 MLCK promoter activity. C: Elk-1 silencing by siRNA prevents the TNF-aeinduced
increase in Caco-2 MLCK mRNA levels. D: Elk-1 silencing by siRNA transfection abolishes TNF-a up-regulation of Caco-2 MLCK protein expression. E: Elk-1 siRNA
transfection prevents the TNF-aeinduced decrease in Caco-2 TER. F: Elk-1 silencing inhibits the TNF-aeinduced increase in mucosal-to-serosal inulin ﬂux.
Data are expressed as means  SEM. nZ 4 (E); nZ 5 (B and F); nZ 8 (C). *P < 0.001, **P < 0.0001 versus control. yP < 0.001, yyP < 0.0001 versus TNF-a
treatment.
TNF-a, TJ Barrier, and ERK1/2 SignalingTNF-a treatment produced a similar proportional increase
in all three DNA constructs (Figure 7, B and C), suggesting
that the presence of the binding site B alone was sufﬁcient to
cause an increase in MLCK promoter activity and that site A
is not required. To validate the requirement of site B in the
regulation of MLCK promoter activity, binding site B was
mutated via site-directed mutagenesis. The mutation of site
B inhibited the TNF-aeinduced increase in promoter ac-
tivity (Figure 8A), conﬁrming that site B was necessary for
the up-regulation of promoter activity. Lastly, the effect of
siRNA-induced silencing of Elk-1 on the TNF-aeinduced
increase in MLCK promoter activity in MLCK 313 was
determined. The siRNA-induced knockdown of Elk-1
inhibited the TNF-aeinduced increase in promoter activ-
ity in MLCK 313 (Figure 8B). Taken together, these data
indicated that Elk-1 binding site B located within the min-
imal promoter region is the regulatory site responsible for
TNF-aeinduced activation of MLCK promoter activity.
The Role of ERK1/2 and Elk-1 in the TNF-aeInduced
Increase in Mouse Intestinal Permeability in Vivo
To this point, our studies suggested that ERK1/2 signaling
cascade activation is required for the TNF-a modulation of
MLCK and TJ permeability in ﬁlter-grown Caco-2 mono-
layers; however, the in vivo relevance of these ﬁndings
remained unclear. We therefore examined the involvement
of the ERK1/2 signaling pathway in TNF-a modulation of
mouse intestinal permeability by recycling intestinal perfu-
sion of mouse small intestine in vivo.31 Intraperitoneal in-
jection of 5 mg of TNF-a caused an increase in intestinalThe American Journal of Pathology - ajp.amjpathol.orgpermeability, as assessed by mucosal-to-serosal ﬂux of a
commonly used paracellular marker, Texas Rededextran
10K (Figure 9A). TNF-a treatment resulted in a time-
dependent increase in ERK1/2 phosphorylation and activa-
tion in the small intestinal tissue (Figure 9, B and C). TNF-a
also caused an increase in intestinal MLCK mRNA and
protein expression (Figure 9, D and E). To conﬁrm the
regulatory role of the ERK1/2 pathway in intestinal MLCK
expression and intestinal permeability in vivo, intestinal
ERK1/2 expression was silenced by in vivo siRNA trans-
fection of small intestine, using a recently described in vivo
transfection methodology.29,31 In brief, 6 cm of mouse
jejunum was isolated using sutures, and the mucosal surface
was exposed to transfection solution containing ERK1/2
siRNA for 1 hour; the sutures were then removed, the in-
testinal segment was reinserted into the original location in
the abdomen, and the abdominal cavity was closed with
sutures. After 2 days, to allow for ERK1/2 depletion, mice
were treated with TNF-a; intestinal permeability studies
were performed on day 3. In vivo ERK1/2 siRNA trans-
fection resulted in a near-complete knockdown of ERK1/2
in the intestinal tissue (Figure 10A). The in vivo siRNA
knockdown of ERK1/2 prevented the TNF-aeinduced in-
crease in intestinal MLCK expression (Figure 10B) and
increase in intestinal permeability (Figure 10C). Taken
together, these results suggest a regulatory role for the
ERK1/2 kinase pathway in TNF-a modulation of intestinal
MLCK expression and intestinal permeability in vivo.
Next, we examined the possible involvement of Elk-1 in
TNF-a modulation of mouse intestinal permeability in vivo.
TNF-a administration caused a time-dependent increase in1879
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Al-Sadi et alintestinal tissue Elk-1 phosphorylation (Figure 11A). Time-
course studies indicated that TNF-aeinduced ERK1/2
activation (Figure 9, B and C) preceded Elk-1 activation.
We also examined the effect of siRNA-induced silencing of
Elk-1 on mouse small intestinal MLCK expression and
mouse intestinal permeability. siRNA-induced knockdown
of Elk-1 in vivo (Figure 11B) resulted in inhibition of the
TNF-aeinduced increase in intestinal tissue MLCK protein
expression and mouse intestinal permeability (Figure 11, B
and C). siRNA-induced knockdown of ERK1/2 also
inhibited the increase in Elk-1 phosphorylation, conﬁrming
that ERK1/2 activation is required for the intestinal tissue
Elk-1 activation in vivo (Figure 11D). Taken together, these
data suggested that the TNF-aeinduced increase in mouse
intestinal permeability in vivo is also mediated by ERK1/2
activation of Elk-1 and by Elk-1edependent increase in
MLCK expression.1880Discussion
The intracellular signaling pathways that mediate TNF-a
modulation of intestinal epithelial TJ barrier remain unclear.
Previous studies from our research group and others indi-
cated that the TNF-a modulation of intestinal TJ barrier
is dependent on MLCK gene activation and protein ex-
pression.6,17e19 With the present studies, we have extended
our previous ﬁndings to delineate the intracellular signaling
cascades that regulate the TNF-a modulation of intestinal
permeability in vitro and in vivo.
The MAP kinase p38 and ERK1/2 pathways play an
important role in mediating many of the TNF-aeinduced
immune responses,24,25 and the ERK1/2 and p38 kinase
pathways are involved in the regulation of growth, differ-
entiation, apoptosis, and inﬂammatory responses.25,35 How-
ever, the involvement of MAP kinase pathways in TNF-a
modulation of intestinal TJ permeability in vitro and in vivo
had not been reported previously. We therefore investigated
the possibility that MAP kinase pathways may play a regu-
latory role in the effect of TNF-a on intestinal TJ perme-
ability. Our results indicate that TNF-a causes activation of
ERK1/2, but not p38 kinase, and that targeted inhibition of
ERK1/2 kinase activity (but not p38 kinase) prevents the
TNF-aeinduced increase in Caco-2 TJ permeability, sug-
gesting that the ERK1/2 signaling pathway (but not theajp.amjpathol.org - The American Journal of Pathology
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Figure 9 Effect of TNF-a on the ERK1/2
signaling pathway in mouse small intestinal tissue
in vivo. A: TNF-a (5 mg) causes an increase in
mouse intestinal mucosal-to-serosal ﬂux of
dextran 10K. B: TNF-a causes a time-dependent
increase in ERK1/2 phosphorylation; total ERK1/
2 was used for equal protein loading. C: TNF-a
causes a time-dependent increase in mouse in-
testinal ERK1/2 activity as determined by ELISA-
based assay. D: TNF-a causes an increase in
mouse MLCK mRNA levels. E: TNF-a causes an in-
crease in mouse MLCK protein expression. Data are
expressed as means  SEM. nZ 6 (C and D); nZ
8 (A). Experimental period, 24 hours (A, D, and E).
*P < 0.001, **P < 0.0001 versus control.
TNF-a, TJ Barrier, and ERK1/2 Signalingp38 kinase pathway) mediates the increase in Caco-2 TJ
permeability.
These ﬁndings contradict recent data from our research
group showing that IL-1b modulation of intestinal epithelial
TJ barrier is dependent on both ERK1/2 and p38 kinase
activation.36,37 Those studies indicated that IL-1b activation
of the p38 kinase pathway is necessary for the IL-
1beinduced increase in Caco-2 TJ permeability, and inhi-
bition of p38 kinase activity prevented the IL-1beinduced
increase in Caco-2 TJ permeability.36 In contrast to earlier
results with IL-1b, in the present studies TNF-a did not
cause an activation of p38 kinase in Caco-2 monolayers, and
the p38 kinase inhibitor SB 203580 did not affect the
TNF-aeinduced increase in Caco-2 TJ permeability. These
results suggest that the effects of IL-1b and TNF-a on Caco-2
TJ barrier are regulated by distinct intracellular processes.
Interestingly, the ERK1/2 signaling pathway has been shown
to have different effects on intestinal epithelial TJ barrier. In
studies using epidermal growth factor, ERK1/2 activation
mediated the intestinal TJ barrier enhancement.38 Similarly,
probiotic enhancement of intestinal TJ barrier also requiredC       TNF    siERK1/2   TNF
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Figure 10 A: ERK1/2 siRNA transfection prevents TNF-aeinduced phosphoryl
increase in mouse MLCK mRNA levels. C: ERK1/2 silencing inhibits the TNF-aeinduc
means  SEM. n Z 4 (B); n Z 6 (C). Experimental period, 2 hours (A); 24 hours
TNF-a treatment.
The American Journal of Pathology - ajp.amjpathol.orgERK1/2 activation.39 In mice, bile-induced enhancement
of intestinal barrier also involved ERK1/2 activation.40 On
the other hand, mycotoxin-induced and IL-1beinduced in-
creases in intestinal epithelial TJ permeability require ERK1/2
activation.37,41 Thus, published data suggest that the ERK1/2
signaling pathway regulates both enhancement and attenuation
of intestinal TJ barrier. How the ERK1/2 signaling pathway
differentially regulates the intestinal TJ barrier requires further
investigation.
Previous studies have shown that the TNF-aeinduced
increase in Caco-2 TJ permeability is associated with an
increase in MLCK gene and protein expression, and inhi-
bition of MLCK expression or MLCK activity prevented the
increase in Caco-2 TJ permeability.6,17e19 In the present
studies, we examined the regulatory role of the ERK1/2
signaling cascade in mediating TNF-a modulation of MLCK
gene activity and protein expression. ERK1/2 inhibitor or
gene silencing studies demonstrated the requirement of
ERK1/2 activation in the TNF-aeinduced increase in
MLCK gene activity and protein expression. As has been
shown previously,6,19 the increase in MLCK expression andl TNF-α siERK1/2
+TNF-α
*
††
control TNF-α siERK1/2
0.00
0.02
0.04
0.06
De
xt
ra
n
 
flu
x 
(m
g/
cm
/h
)
**
††
+TNF-α
ation of ERK1/2. B: ERK1/2 siRNA transfection inhibits the TNF-aeinduced
ed increase in mucosal-to-serosal ﬂux of dextran 10K. Data are expressed as
(B and C). *P < 0.001, **P < 0.0001 versus control. yyP < 0.0001 versus
1881
P-Elk-1
0     2        4        6   24Time (h)
Total Elk-1
MLCK
C         TNF        siElk-1 siElk-1
+TNF                      
Elk-1
β actin
P-Elk-1
actin
C        T         siNT siNT+T siERK1/2 siERK1/2 +T
D
ex
tra
n
 fl
ux
 
(m
g/c
m/
h)
control TNF-α siElk-1
0.00
0.02
0.04
0.06
+TNF-α
**
††
Figure 11 A: TNF-a causes a time-dependent
increase in Elk-1 phosphorylation; total ERK1/2
was used for equal protein loading. B: Elk-1 siRNA
transfection results in a near-complete depletion of
mouse intestinal Elk-1 protein expression and pre-
vents the TNF-aeinduced increase in mouse intes-
tinal MLCK protein expression. C: Elk-1 silencing
inhibits the TNF-aeinduced increase in mucosal-
to-serosal ﬂux of dextran 10K. D: siRNA-induced
knockdown of ERK1/2 prevents TNF-aeinduced
phosphorylation of Elk-1 in mouse intestinal tissue.
Data are expressed as means  SEM. n Z 3.
Experimental period, 24 hours (B and C); 4 hours
(D). **P < 0.0001 versus control. yyP < 0.0001
versus TNF-a treatment.
Al-Sadi et alactivity was responsible for the TNF-aeinduced increase in
Caco-2 TJ permeability. Presumably, the increase in MLCK
activity leads to myosin light chain phosphorylation and
myosin-Mg2þ-ATPaseedependent opening of the intestinal
TJ barrier.42
As for the molecular mechanisms that regulate the
MLCK gene activation and gene transcription, our studies
suggest that the nuclear transcription factor Elk-1 is an
important mediator of MLCK gene activity and Caco-2
TJ permeability. Elk-1 belongs to the ETS domain
transcription factor family and the ternary complex factor
subfamily and is a direct substrate of ERK1/2.34,43e45 On
activation, Elk-1 forms a ternary complex with the serum
response factor protein and binds to the serum response
element, inducing activation of the target gene.34 Serine
phosphorylation of Elk-1 (Ser383 and Ser389) is neces-
sary for the transcriptional regulation. ERK1/2 is known
to induce phosphorylation and activation of Elk-1.33,34,46
Our present results show that TNF-a causes ERK1/2-
dependent phosphorylation and activation of Elk-1.
Moreover, inhibition of ERK1/2 activation or ERK1/2
knockdown prevented TNF-a activation of Elk-1, sug-
gesting that Elk-1 activation is directly regulated by
ERK1/2. Our results also showed that Elk-1 plays an
essential role in TNF-a up-regulation of MLCK, and
siRNA silencing of Elk-1 inhibited the increase in
MLCK gene activity and mRNA transcription and also
inhibited the increase in Caco-2 TJ permeability. Our
promoter binding studies demonstrated binding of acti-
vated Elk-1 to the putative binding site (serum response
element) on the MLCK promoter region, and site-
directed mutagenesis studies conﬁrmed the requirement
of the serum response element in TNF-a up-regulation
of the promoter activity. Thus, our data suggest that
binding of activated Elk-1 to the serum response element
is important in the regulation of MLCK promoter activ-
ity. Taken together, our ﬁndings suggest that the ERK1/
2 activation of Elk-1 leads to MLCK promoter activation
and subsequent increase in MLCK mRNA transcription1882and translation and MLCK-dependent opening of the
Caco-2 TJ barrier.
We also examined the in vivo mechanisms of TNF-a
regulation of intestinal permeability, using recycling intes-
tinal perfusion of isolated segment of mouse small intestine
in vivo. In previous studies, intraperitoneal administration of
TNF-a resulted in an increase in intestinal permeability to
dextran 10K.31 In the present studies, the increase in mouse
intestinal permeability was associated with an increase in
ERK1/2 activity, and intestinal tissueespeciﬁc silencing of
ERK1/2 completely inhibited the TNF-aeinduced increase
in mouse intestinal permeability, suggesting that the TNF-
aeinduced increase in intestinal permeability is regulated
by the ERK1/2 signaling pathway. Our in vivo studies also
indicated that TNF-a causes an ERK1/2-dependent activa-
tion of Elk-1 and that Elk-1 activation was required for the
TNF-aeinduced increase in intestinal MLCK expression
and intestinal permeability. These data suggest that a similar
signaling mechanism regulates the effect of TNF-a on in-
testinal permeability both in vivo and in vitro. Our studies
also suggest that in vivo targeting of ERK1/2 signaling
pathways is effective in preventing the TNF-aeinduced
increase in intestinal permeability. To our knowledge, this is
the ﬁrst study to show that the in vivo activation of the
ERK1/2 signaling pathway regulates the TNF-aeinduced
increase in intestinal permeability.
In conclusion, our results provide new insight into the
intracellular signaling pathways and molecular processes
that regulate TNF-a modulation of intestinal TJ perme-
ability. The ﬁndings suggest that TNF-a causes a rapid
activation of ERK1/2, which in turn leads to phosphoryla-
tion and activation of Elk-1; the activated Elk-1 binds to the
serum response element on the MLCK promoter, leading to
MLCK gene activation, transcription, protein expression,
and MLCK-dependent opening of the intestinal TJ barrier.
Our in vivo studies also demonstrated the feasibility of
therapeutic targeting of ERK1/2 and Elk-1 to prevent the
TNF-aeinduced increase in intestinal TJ permeability
in vivo.ajp.amjpathol.org - The American Journal of Pathology
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